The current operating model of medicines supply requires transparent global collaboration to provide access to medicines for patients around the world.
The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today requested urgent action by governments and pharmaceutical supply chain stakeholders to reopen air freight routes and ensure patients around the globe can continue to have access to the medicines they need during the COVID-19 pandemic.
IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today calls upon the global policy leaders and governments to do everything in their power to keep the manufacturing operations and the supply chain of essential medicines operating at full capacity. This will allow our companies to continue to produce much needed critical medicines. While we support the need to protect healthcare workers and to provide hospitals with essential materials, putting unreasonable restrictions on exports of essential medical supplies or medicines will do more harm than good at this time of urgent need.
- Hanan Sboul takes over the position of IGBA Chair (January 2020)
- IGBA applauds long-awaited scientific harmonization process of bioequivalence studies (December 2019)
- IGBA Statement on Hosting of Pat-INFORMED by WIPO (December 2019)
- WHO signs MoU with International Generic and Biosimilar Medicines Association to promote access (October 2019)